TheraRadar
← Back
Data updated: Jun 28, 2026

WELDERS SUPPLY COMPANY OF LOUISVILLE INC

Pharma
Pharmaceuticals

WELDERS SUPPLY COMPANY OF LOUISVILLE INC is a pharmaceutical company with 1 FDA-approved products.

2025
Since
1
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
1 Small Molecules

WELDERS SUPPLY COMPANY OF LOUISVILLE INC's Key Drugs

WELDERS SUPPLY COMPANY OF LOUISVILLE INC's core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013

WELDERS SUPPLY COMPANY OF LOUISVILLE INC's Recent FDA Approvals

WELDERS SUPPLY COMPANY OF LOUISVILLE INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

WELDERS SUPPLY COMPANY OF LOUISVILLE INC's Therapeutic Areas

Disease areas where WELDERS SUPPLY COMPANY OF LOUISVILLE INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

WELDERS SUPPLY COMPANY OF LOUISVILLE INC Pipeline Snapshot

Active clinical trials for WELDERS SUPPLY COMPANY OF LOUISVILLE INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling